Gosset Ownership
Private
Employees
~1
Therapeutic Areas
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Azora Therapeutics General Information
Azora Therapeutics is a clinical-stage biopharmaceutical company spun out of Stanford University’s SPARK program. It develops novel small molecule therapies—specifically oral and topical aryl hydrocarbon receptor agonists—for serious autoimmune and inflammatory diseases. Its lead programs target hidradenitis suppurativa, ulcerative colitis, and psoriasis. The company has completed or nearly completed several Phase 1b studies as of early/mid–2023. It owns worldwide royalty-free rights to its technology.[1][4][6][8]
Contact Information
Primary Industry
Biotech
Corporate Office
Encino, California
United States
United States
Drug Pipeline
AT193
Phase 1Key Partnerships
Collaborations with academic institutions including Stanford University via the SPARK program [6]
Azora Therapeutics Funding
No funding data available
To view Azora Therapeutics's complete valuation and funding history, request access »